Baidu
map

Chest:吸氧对COPD患者6分钟步行试验结果的短期影响

2017-04-17 xiangting MedSci原创

与NOX相比, HYX和EIH患者能通过吸氧增加运动能力。然而达到临床改善阈值的患者还不到一半。这些氧气应答者的特点是运动能力水平显著下降。

COPD患者运动中吸氧的急性期反应与正常人有明显不同。但是什么因素影响了氧气反应仍然未知。近日呼吸领域权威杂志Chest上发表了一篇文章,旨在探讨吸氧对COPD患者6分钟步行结果的影响。

采用随机、单盲的方式,124COPD患者分别进行两次6分钟步行试验,其中一次吸入氧气(6MWTO2),另外一次吸入室内空气。两种气体均通过标准鼻塞(2L / min)输送。为了便于分析,按PaO2值将患者分层比较:(134例静息低氧血症(HYX)患者;(243例运动性低氧血症患者(EIH);(331例正常血氧(NOX)。

研究结果显示,吸氧使得整个队列(27±42米,P <0.001)、HYX亚组(37±40米,P <0.001)和EIH亚组(28 ±44米,P <0.0016分钟步行距离增加,而NOX亚组(15±43米,P = 0.065)无增加。42%HYX患者和47%EIH患者通过吸氧将6分钟步行距离改善至临床相关程度(≥30米)。与没有反应的患者相比,这些氧气应答者的特征是使用室内空气6分钟步行距离显著下降(306±106米对358±113米; P <0.05)。尽管6MWTO2的氧饱和度明显高于所有3个亚组吸入室内空气时的氧饱和度,但73.5%HYX患者在6MWTO2期间,氧饱和度降至88%以下。

由此可见,与NOX相比, HYXEIH患者能通过吸氧增加运动能力。然而达到临床改善阈值的患者还不到一半。这些氧气应答者的特点是运动能力水平显著下降。

原始出处:

Inga Jarosch, MSc, et al. Short-term Effects of Supplemental Oxygen on 6-Min Walk Test Outcomes in Patients With COPD: A Randomized, Placebo-Controlled, Single-blind, Crossover Trial. Chest. April 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675200, encodeId=912e16e5200f9, content=<a href='/topic/show?id=2e89151259' target=_blank style='color:#2F92EE;'>#6分钟步行试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1512, encryptionId=2e89151259, topicName=6分钟步行试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fd727178502, createdName=JR19860228, createdTime=Sun Mar 18 18:49:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654816, encodeId=ab1d16548165a, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Mon Nov 13 13:49:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050646, encodeId=5b462050646f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 03 07:49:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929312, encodeId=8e1b192931262, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Mar 19 10:49:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488794, encodeId=2adc1488e942e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Apr 19 00:49:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675200, encodeId=912e16e5200f9, content=<a href='/topic/show?id=2e89151259' target=_blank style='color:#2F92EE;'>#6分钟步行试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1512, encryptionId=2e89151259, topicName=6分钟步行试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fd727178502, createdName=JR19860228, createdTime=Sun Mar 18 18:49:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654816, encodeId=ab1d16548165a, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Mon Nov 13 13:49:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050646, encodeId=5b462050646f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 03 07:49:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929312, encodeId=8e1b192931262, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Mar 19 10:49:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488794, encodeId=2adc1488e942e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Apr 19 00:49:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-11-13 yuanming15
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675200, encodeId=912e16e5200f9, content=<a href='/topic/show?id=2e89151259' target=_blank style='color:#2F92EE;'>#6分钟步行试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1512, encryptionId=2e89151259, topicName=6分钟步行试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fd727178502, createdName=JR19860228, createdTime=Sun Mar 18 18:49:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654816, encodeId=ab1d16548165a, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Mon Nov 13 13:49:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050646, encodeId=5b462050646f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 03 07:49:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929312, encodeId=8e1b192931262, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Mar 19 10:49:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488794, encodeId=2adc1488e942e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Apr 19 00:49:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675200, encodeId=912e16e5200f9, content=<a href='/topic/show?id=2e89151259' target=_blank style='color:#2F92EE;'>#6分钟步行试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1512, encryptionId=2e89151259, topicName=6分钟步行试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fd727178502, createdName=JR19860228, createdTime=Sun Mar 18 18:49:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654816, encodeId=ab1d16548165a, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Mon Nov 13 13:49:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050646, encodeId=5b462050646f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 03 07:49:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929312, encodeId=8e1b192931262, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Mar 19 10:49:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488794, encodeId=2adc1488e942e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Apr 19 00:49:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2018-03-19 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=1675200, encodeId=912e16e5200f9, content=<a href='/topic/show?id=2e89151259' target=_blank style='color:#2F92EE;'>#6分钟步行试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1512, encryptionId=2e89151259, topicName=6分钟步行试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fd727178502, createdName=JR19860228, createdTime=Sun Mar 18 18:49:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654816, encodeId=ab1d16548165a, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Mon Nov 13 13:49:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050646, encodeId=5b462050646f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 03 07:49:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929312, encodeId=8e1b192931262, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Mar 19 10:49:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488794, encodeId=2adc1488e942e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Apr 19 00:49:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-04-19 gous

相关资讯

The Lancet:BDP/FF/GB三联制剂对COPD病情控制效果更佳

对于症状性,FEV1小于50%并有恶化历史的慢性阻塞性肺病患者,使用BDP/FF/GB三联超细粉混合制剂较单独使用格隆溴铵对病情控制更为有效

Lancet:单次吸入超细三联疗法与长效毒蕈碱受体拮抗剂治疗慢性阻塞性肺疾病哪个好?

在这个三位一体的研究中,采用超细固定三联疗法治疗有症状的COPD、FEV1小于50%且有加重病史的患者相比于噻托溴铵治疗具有临床效益。

Plos One:美丽的蒙古,人群发生气流受限现状如何呢?

慢性阻塞性肺疾病(COPD)的负担将在未来几十年内显著增加。目前,在蒙古乌兰巴托,与COPD发病密切相关的空气污染问题日益受到关注。然而,乌兰巴托的COPD人群流行现状仍然不清楚。近期,一项发表在杂志Plos One上的研究旨在估计气流受限的流行情况,并调查蒙古人口气流受限与推定危险因素之间的关系。研究者们在乌兰巴托进行了五次横断面的研究。生活在乌兰巴托的40岁至79岁的746名受试者完成了问卷调

Cell Physiol Biochem:COPD吸入性药物治疗的更优选择

近期,Cell Physiol Biochem杂志中有一篇文章报道,对于慢性阻塞性肺疾病(COPD)的吸入性药物治疗,他们进行进一步的研究。得出ICS + LABA + LAMA三联用药患者能获得最佳的疗效。研究背景:常规治疗COPD的吸入性药物共分为3大类:ICS、LABA 、LAMA。为了提高药物的疗效,通常但以药物的吸入治疗被联合治疗所替代。然而,这种用法缺乏大规模的临床试验来作为证据支撑。

Eur Respir J: ERS(欧洲呼吸学会)/ATS(美国胸科学会)指南: COPD急性加重的管理

COPD慢性进展常常伴随"急性加重",临床定义为以呼吸系统症状增加,尤其呼吸困难、咳嗽、痰液产生以及痰液化脓增加为特征的事件。COPD急性加重对COPD患者生存质量有不利影响,加速疾病进程以及导致入院和死亡。本指南的目的是更新COPD急性加重患者管理的建议以及针对现有指南未涉及的相关具体问题进行解答。以下六个问题采用系统性回顾,依据证据质量和推荐强度分级(GRADE)给出治疗建议。

Thromb Haemost:SCAD的治疗—替格瑞洛能否取代氯吡格雷?

近期,Thromb Haemost杂志中的一篇报道,对替格瑞洛与氯吡格雷,在稳定性冠脉疾病(SCAD)伴有慢性阻塞性肺疾病(COPD)患者中的疗效进行了对比。这两种药物中,哪种药物对于改善动脉内皮功能的作用更优呢?对于SCAD合并有COPD的患者,其心血管不良事件的发生率较一般人显着提高。慢性炎症、上皮功能失调、氧化应激、及血小板活性(PR)的增强均是不良事件的诱因。46名SCAD合并COPD的患

Baidu
map
Baidu
map
Baidu
map